Search results
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 2 days agoDespite the...to moderate in severity, with serious adverse events linked to the treatment generally...
State-funded testing of COVID-19 treatment needs SC volunteers
South Carolina Daily Gazette via Yahoo News· 5 days agoCOLUMBIA – An international trio of chemists — two from Germany and one from the Czech Republic —...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 1 day agoFG-M701, a novel TL1A inhibitor, is in pre-clinical development. These next-generation IBD therapies...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 2 days agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 3 days agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy ...
Can money conquer death? How wealthy people are trying to live forever
San Jose Mercury News· 8 hours agoPeter Diamandis, a week away from turning 63, bounds out of a Starbucks on a recent morning with a...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks· 3 days agoFree Report) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular dystrophy (“DMD”) failed to meet the primary endpoint ...
Carpal Tunnel Syndrome: AAOS Updates Clinical Prac | Newswise
Newswise· 5 days agoROSEMONT, Ill. (June 11, 2024)—The American Academy of Orthopaedic Surgeons (AAOS) issued an update to the Clinical Practice Guideline (CPG) for Management of Carpal Tunnel ...